Shahrzad Zangooie,Reza Ghanbari,Farid Azizi Jalilian et al.
Shahrzad Zangooie et al.
Background: This in vitro study aimed to investigate the effect of several phenolic compounds, including doxorubicin, quercetin, and resveratrol, on HSV-1 infection. ...
Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study [0.03%]
恩曲他滨搭配阿巴呋伏昔与特诺福韦艾拉酚胺治疗高病毒载量慢性乙型肝炎初始48周疗效和安全性的比较：一项单中心回顾性研究
Qing Zhang,Jianhua Xu,Dan Liu et al.
Qing Zhang et al.
Background/aim: Tenofovir amibufenamide (TMF) employs innovative ProTide technology and a methylation strategy to enhance the lipid solubility and plasma stability of the amide bond, providing advantages over tenofovir al...
Comparative Study
Antiviral therapy. 2024 Oct;29(5):13596535241284226. DOI:10.1177/13596535241284226 2024
Clinical outcomes in patients with mild to moderate coronavirus disease 2019 treated with monoclonal antibody therapy versus an untreated control cohort [0.03%]
与未接受治疗的对照组相比单克隆抗体疗法对轻中度新型冠状病毒肺炎患者临床转归的影响
Courtney N Nichols,Mark Lustberg,Mohammed Mahdee E Sobhanie et al.
Courtney N Nichols et al.
Background: Monoclonal antibody therapy (MAT) received Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for mild to moderate COVID-19 treatment in adults at a high-risk for progression to severe diseas...
Andrographolide suppresses SARS-CoV-2 infection by downregulating ACE2 expression: A mechanistic study [0.03%]
andrographolide通过下调ace2表达抑制新冠病毒感染：机制研究
Qing Li,Hongmei Lu,Yongdui Ruan et al.
Qing Li et al.
Angiotensin-converting enzyme 2 (ACE2) is the receptor that enables SARS-CoV-2 to invade host cells. Previous studies have reported that reducing ACE2 expression may have an anti-SARS-CoV-2 effect. In this study, we constructed a pGL4.10-F2...
In-silico approach to characterize the structure and function of a hypothetical protein of Monkeypox virus exploring Chordopox-A20R domain-containing protein activity [0.03%]
基于计算的表征猴痘病毒假想蛋白质结构和功能的方法并探索弦多瘤病毒感染A20R区域含有的蛋白质活性
Md Iqbal Hosen,Md Easin Mia,Md Nur Islam et al.
Md Iqbal Hosen et al.
Background: Monkeypox has emerged as a noteworthy worldwide issue due to its daily escalating case count. This illness presents diverse symptoms, including skin manifestations, which have the potential to spread through contact. The transmi...
Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1-infected children aged ≥6 to <12 years, using matching placebo tablets: A randomized study [0.03%]
评估利匹韦林分散片在HIV-1感染儿童中的吞咽性和可接受性：一项在中国开展的开放标签、多中心研究
Sandy Van Hemelryck,Erika Van Landuyt,Veerle Hufkens et al.
Sandy Van Hemelryck et al.
Background: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) was developed as a once-daily, complete antiretroviral (ARV) regimen therapy to address the need for simplified...
Adverse drug reactions attributed to generic substitution of antiretroviral medications among HIV treatment and pre-exposure prophylaxis clients in British Columbia, Canada [0.03%]
加拿大不列颠哥伦比亚省HIV治疗和暴露前预防客户的抗逆转录病毒药物通用替代引起的不良药物反应
Katherine J Lepik,Olivia L Hunt,Nic Bacani et al.
Katherine J Lepik et al.
Background: In British Columbia, antiretrovirals (ARVs) for HIV treatment (HIV-Tx) and pre-exposure prophylaxis (PrEP) are free-of-charge through publicly-funded Drug Treatment Programs (DTPs). When available, less costly...
Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection [0.03%]
异体干细胞移植患者中发生对bamlanivimab耐药并筛选出E484K突变的院内SARS-CoV-2感染
Inès Boussen,Maud Salmona,Flore Sicre De Fontbrune et al.
Inès Boussen et al.
We report the case of an allogeneic stem cell transplant recipient with nosocomial acquisition of SARS-CoV-2 infection who received antispike neutralizing monoclonal antibody bamlanivimab 2 days after diagnosis of SARS-CoV-2 infection but p...
Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA [0.03%]
CAPELLA研究中截至第52周进入抑制剂和lenacapavir的交叉耐药性
Nicolas Margot,Nina Pennetzdorfer,Vidula Naik et al.
Nicolas Margot et al.
Background: Lenacapavir (LEN) is a first-in-class inhibitor of human immunodeficiency virus type 1 (HIV-1) capsid function for the treatment of heavily treatment-experienced people with HIV (PWH) harbouring multidrug resi...
Dolutegravir and rilpivirine as successful initial antiretroviral therapy in a treatment-naive patient with HIV-1: A case report [0.03%]
一线使用多替拉韦和利匹韦林治疗HIV-1感染的效果良好：一例报道
S Jawad Zafar,Bruce L Gilliam,Sarah A Schmalzle
S Jawad Zafar